Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Phenotypic variability and risk of malignancy in SDHC-linked paragangliomas: lessons from three unrelated cases with an identical germline mutation (p.Arg133*).

Bickmann JK, Sollfrank S, Schad A, Musholt TJ, Springer E, Miederer M, Bartsch O, Papaspyrou K, Koutsimpelas D, Mann WJ, Weber MM, Lackner KJ, Rossmann H, Fottner C.

J Clin Endocrinol Metab. 2014 Mar;99(3):E489-96. doi: 10.1210/jc.2013-3486. Epub 2014 Jan 1.

PMID:
24423348
2.

Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL).

Zovato S, Kumanova A, Demattè S, Sansovini M, Bodei L, Di Sarra D, Casagranda E, Severi S, Ambrosetti A, Schiavi F, Opocher G, Paganelli G.

Horm Metab Res. 2012 May;44(5):411-4. doi: 10.1055/s-0032-1311637. Epub 2012 May 7.

PMID:
22566197
3.

Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior.

Ghayee HK, Havekes B, Corssmit EP, Eisenhofer G, Hammes SR, Ahmad Z, Tessnow A, Lazúrová I, Adams KT, Fojo AT, Pacak K, Auchus RJ.

Endocr Relat Cancer. 2009 Mar;16(1):291-9. doi: 10.1677/ERC-08-0214. Epub 2008 Dec 15.

Supplemental Content

Loading ...
Support Center